the benefits of glp-1 drugs beyond obesity agonists and changes in body mass and composition in adults with overweight or with or without type 2 diabetes mellitus: a systematic review and meta-analysis The world’s largest study on

About 1 in 8 Americans report trying a GLP-1, while more and more Americans are investigating psychedelics for mental health treatment

The evidence is still early

Practical access strategies For patients in markets where both peptides are available, tirzepatide is the practical choice due to established availability, known dosing protocols, extensive clinical experience, and insurance coverage pathways

The difference between compounded versions of these medications and name brands comes down to regulation and safety

Multiple case reports have noted marked improvements in AN in patients with and without obesity with the addition of metformin to their existing treatment regimens in doses ranging from 500 mg to 1700 mg daily

The bridge program will allow enrollees in Medicare, the federal health program for adults 65 and older, to get weight-loss drugs at prices negotiated under President Donald Trump's most favored nation agreements with Eli Lilly and Novo Nordisk